KemPharm (KMPH) stock price, revenue, and financials

KemPharm market cap is $42 m, and annual revenue was $12.84 m in FY 2019

$42 M

KMPH Mkt cap, 28-Sept-2020

$6.9 M

KemPharm Revenue Q2, 2020
KemPharm Net income (Q2, 2020)859 K
KemPharm EBIT (Q2, 2020)2.6 M
KemPharm Cash, 30-Jun-20206.4 M
KemPharm EV103.7 M

KemPharm Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

12.8m

Cost of goods sold

10.0m

Gross profit

2.8m

Gross profit Margin, %

22%

R&D expense

13.9m20.5m20.6m41.8m19.4m

General and administrative expense

8.9m14.0m12.8m12.5m10.8m

Operating expense total

22.8m34.5m33.4m54.3m23.2m

EBIT

(22.8m)(37.5m)(33.4m)(55.9m)(20.3m)

EBIT margin, %

(158%)

Interest expense

31.8m21.0m10.1m689.0k4.2m

Interest income

32.0k353.0k365.0k420.0k309.0k

Pre tax profit

(54.6m)(16.5m)(43.4m)(56.6m)(24.5m)

Income tax expense

26.0k(15.0k)(43.0k)(126.0k)(22.0k)

Net Income

(54.7m)(16.5m)(43.4m)(56.5m)(24.5m)

KemPharm Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

32.3m16.8m10.9m18.4m3.2m

Accounts Receivable

2.0m140.0k1.7m

Prepaid Expenses

1.7m2.1m1.6m

Inventories

2.8m489.0k

Current Assets

54.1m74.4m47.0m23.7m6.6m

PP&E

403.0k2.0m2.0m1.8m1.5m

Total Assets

55.7m84.9m52.5m26.7m10.5m

Accounts Payable

4.9m6.4m2.2m3.7m1.1m

Short-term debt

3.3m3.3m80.2m

Current Liabilities

8.3m6.6m11.5m12.0m5.4m

Long-term debt

92.7m81.4m77.3m

Total Debt

96.1m84.8m157.5m

Total Liabilities

103.6m110.0m93.3m85.0m

Common Stock

1.0k3.0k4.0k

Preferred Stock

Additional Paid-in Capital

94.7m102.6m107.2m154.6m171.3m

Retained Earnings

(104.8m)(121.3m)(164.7m)(221.2m)(245.7m)

Total Equity

(10.1m)(18.7m)(57.5m)(66.6m)(74.5m)

Debt to Equity Ratio

-1.7 x-1.3 x

Debt to Assets Ratio

1.8 x3.2 x

Financial Leverage

-5.5 x-4.5 x-0.9 x-0.4 x-0.1 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

10.3m64.2m59.0m77.3m27.5m20.8m12.9m12.4m7.8m8.8m16.5m1.8m13.4m7.3m6.5m2.4m6.4m

Accounts Receivable

2.5m1.5m1.6m2.3m2.1m

Prepaid Expenses

53.0k607.0k607.0k386.0k824.0k636.0k795.0k771.0k1.4m1.8m1.6m2.6m1.9m1.3m528.0k890.0k603.0k

Current Assets

10.3m64.8m59.6m111.4m84.6m65.3m63.0m55.4m50.2m39.1m30.9m16.7m15.3m8.6m8.7m5.5m9.1m

PP&E

354.0k352.0k386.0k443.0k1.1m1.5m2.2m2.1m2.1m1.9m1.8m1.8m1.7m1.6m1.5m1.2m1.1m

Total Assets

14.1m66.5m61.4m111.9m104.6m94.5m75.6m69.0m59.3m42.6m34.0m18.7m19.9m13.0m12.9m8.9m12.3m

Accounts Payable

4.0m4.9m4.0m4.2m5.4m5.6m4.6m6.3m6.4m10.2m14.0m14.7m8.2m7.9m3.1m6.4m4.7m

Short-term debt

32.0k32.0k32.0k18.0k103.0k105.0k162.0k177.0k180.0k187.0k190.0k210.0k68.6m67.3m

Current Liabilities

4.0m4.9m6.8m5.8m7.4m5.7m4.8m6.6m6.6m13.8m17.6m18.3m15.2m15.0m10.4m75.6m72.5m

Long-term debt

50.0k50.0k50.0k515.0k466.0k451.0k2.1m2.0m2.0m68.6m781.0k

Total Debt

82.0k11.0k82.0k18.0k103.0k105.0k162.0k177.0k180.0k702.0k656.0k661.0k2.1m2.0m2.0m137.2m68.1m

Total Liabilities

40.3m63.1m67.2m123.4m104.3m104.3m109.6m108.3m107.4m122.3m117.5m114.1m94.7m94.6m83.5m77.6m75.2m

Common Stock

2.0k3.0k3.0k1.0k1.0k1.0k1.0k1.0k1.0k2.0k2.0k2.0k3.0k3.0k3.0k6.0k7.0k

Preferred Stock

Additional Paid-in Capital

1.8m89.3m89.9m96.3m98.3m101.6m103.7m104.9m106.1m111.3m117.4m120.7m158.6m161.2m169.1m182.8m187.7m

Retained Earnings

(56.1m)(85.9m)(95.6m)(107.8m)(98.0m)(111.4m)(137.7m)(144.2m)(154.2m)(190.9m)(200.9m)(216.0m)(233.5m)(242.7m)(239.7m)(251.5m)(250.6m)

Total Equity

(54.4m)3.5m(5.7m)(11.5m)333.0k(9.8m)(33.9m)(39.3m)(48.1m)(79.7m)(83.5m)(95.3m)(74.8m)(81.5m)(70.6m)(68.7m)(62.9m)

Debt to Equity Ratio

0 x0 x0 x0 x0.3 x0 x0 x0 x0 x0 x0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0.1 x0.2 x

Financial Leverage

-0.3 x19.2 x-10.7 x-9.7 x314.2 x-9.6 x-2.2 x-1.8 x-1.2 x-0.5 x-0.4 x-0.2 x-0.3 x-0.2 x-0.2 x-0.1 x-0.2 x

KemPharm Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(54.7m)(16.5m)(43.4m)(56.5m)(24.5m)

Depreciation and Amortization

84.0k175.0k336.0k324.0k304.0k

Accounts Receivable

(4.5m)(1.7m)

Inventories

(1.2m)(15.9m)

Accounts Payable

1.3m1.1m(801.0k)(1.6m)(3.8m)

Cash From Operating Activities

(20.3m)(29.8m)(33.1m)(54.2m)(23.7m)

Purchases of PP&E

(135.0k)(643.0k)(181.0k)(21.0k)(26.0k)

Cash From Investing Activities

(19.1m)(46.9m)27.4m33.3m3.2m

Long-term Borrowings

(157.0k)(193.0k)(207.0k)

Cash From Financing Activities

61.5m61.2m(203.0k)28.0m4.9m

Net Change in Cash

(5.9m)7.1m(15.6m)

Interest Paid

3.0k3.3m5.7m5.6m5.4m

KemPharm Ratios

USDQ1, 2015

Financial Leverage

-0.3 x